Elevation Oncology(@elevationonc) 's Twitter Profile Photo

May is !

Join us in celebrating the scientists whose dedication to research saves millions of lives. Visit our website to discover how we contribute to the cause.

elevationoncology.com

account_circle
Calyx(@calyxai) 's Twitter Profile Photo

Proud to have supported Iovance on this approval – the first tumor-infiltrating lymphocyte ( ) therapy for – and excited about its impact on patients & the research community. calyx.ai/s/9n18

account_circle
POEM Group(@poem_group) 's Twitter Profile Photo

Additional talks and a panel discussion during session 2 of POEM Virtual symposium highlighting the role and importance of genomic testing in Pediatric solid tumors.

Additional talks and a panel discussion during session 2  of POEM Virtual symposium highlighting the role and importance of genomic testing in Pediatric solid tumors. 
 #solidtumors #pediatriccancer #Genomics #POEM
account_circle
TScan Therapeutics(@TScan_Tx) 's Twitter Profile Photo

We are proud to announce that the first patient has been dosed in our Phase 1 trial evaluating TCR-T therapy for the treatment of . The patient was dosed with TSC-203-A0201 targeting the cancer-associated antigen PRAME. Learn more: bit.ly/3UqZrAA

We are proud to announce that the first patient has been dosed in our Phase 1 trial evaluating TCR-T therapy for the treatment of #SolidTumors. The patient was dosed with TSC-203-A0201 targeting the cancer-associated antigen PRAME. Learn more: bit.ly/3UqZrAA
account_circle
Triumvira Immunologics(@Triumvirainc) 's Twitter Profile Photo

Our TAC-T technology contains an intracellular co-receptor domain that binds directly to native receptors, steering the body’s natural immune response to attack .

Learn more: bit.ly/48mZX7O

Our TAC-T technology contains an intracellular co-receptor domain that binds directly to native #Tcell receptors, steering the body’s natural immune response to attack #solidtumors.

Learn more: bit.ly/48mZX7O
account_circle
Affini-T Therapeutics(@affinit_tx) 's Twitter Profile Photo

Tuning in to the 23rd Annual Needham & Company Healthcare Conference? Connect virtually with our CFO, Kathy Bergsteinsson, to learn more about our work targeting mutations in .

Tuning in to the 23rd Annual Needham & Company Healthcare Conference? Connect virtually with our CFO, Kathy Bergsteinsson, to learn more about our work targeting #oncogenicdriver mutations in #solidtumors.
account_circle
SoniaGuedan(@GuedanS) 's Twitter Profile Photo

Come today to see our poster 1242 at ⁦ASGCT⁩ , 'Dissecting the Mechanisms of CAR-T Cell Dysfunction in a Mouse Model of Solid Tumors', presented by the super talented PhD student Paula Barbao. It's a bit hidden, but you can’t miss it!

Come today to see our poster 1242 at ⁦@ASGCTherapy⁩ , 'Dissecting the Mechanisms of CAR-T Cell Dysfunction in a Mouse Model of Solid Tumors', presented by the super talented PhD student Paula Barbao. It's a bit hidden, but you can’t miss it! #asgct2023 #cart #solidtumors
account_circle
Teiko bio(@TeikoBio) 's Twitter Profile Photo

Exciting keynote by Dr. Dr Marcela Maus of MGH on & . Loss of IFNyR signaling in solid tumors can drive resistance and CAR-T cytotoxicity suggesting a “crucial role of IFNyR in stabilizing and enhancing solid tumor CAR T cell interactions.”

Exciting #IO360nyc keynote by Dr. @MarcelaMaus of MGH on #solidtumors & #CART. Loss of IFNyR signaling in solid tumors can drive resistance and CAR-T cytotoxicity suggesting a “crucial role of IFNyR in stabilizing and enhancing solid tumor CAR T cell interactions.”#CancerResearch
account_circle
Ahmad Tarhini(@ATarhiniMDPhD) 's Twitter Profile Photo

Society for Immunotherapy of Cancer⁩ │ Abstract 151 heterogeneity between paired primary & metastatic & implications for -based personalized cancer │ Oncology Research Information Exchange Network (ORIEN) Team Science ⁦Moffitt Cancer Center

#SITC23 ⁦@sitcancer⁩ │ Abstract 151 #Genetic heterogeneity between paired primary & metastatic #solidtumors & implications for #neoantigen -based personalized cancer #vaccines │ Oncology Research Information Exchange Network (ORIEN) Team Science ⁦@MoffittNews⁩
account_circle
Pharmacological Research(@PharmacolRes) 's Twitter Profile Photo

Preclinical study showed that the depletion of regulatory T cells increases the anti-tumor effect of in situ vaccination in multiple solid tumors: doi.org/10.1016/j.phrs…

Preclinical study showed that the depletion of regulatory T cells increases the anti-tumor effect of in situ vaccination in multiple solid tumors: doi.org/10.1016/j.phrs…
#Tcells #solidtumors #PharmacolRes #openaccess #Research #PharmaTwitter #MedTwitter
account_circle
Affini-T Therapeutics(@affinit_tx) 's Twitter Profile Photo

We’re live in at the ASGCT 27th Annual Meeting! Stop by and meet with our team during today’s poster session. More details here: bit.ly/3QApRP8 and bit.ly/3UPmdDD. therapies

We’re live in #Baltimore at the @ASGCTherapy 27th Annual Meeting! Stop by and meet with our team during today’s poster session. More details here: bit.ly/3QApRP8 and bit.ly/3UPmdDD. #ASGCT24 #geneediting #Tcell therapies #solidtumors
account_circle
European Hematology Association(@EHA_Hematology) 's Twitter Profile Photo

It is the final day of the -The EBMT 6th European CAR T-cell Meeting . Join us today for sessions on , , & a keynote lecture by Fabio Ciceri. Today is your final chance to browse posters in person.

View the program: eha.fyi/CART2024_Progr…

account_circle
raffaellagreco(@RaffaellaGrecoM) 's Twitter Profile Photo

Don’t miss ‘W10 Cellular therapy in other disease’ on April 17 (10:30 – 11:45 bst) at . Overview, new insights & recommendations (library.ebmt.org/category4/docu…) on the use of in and
The EBMT The EBMT_Trainee
🌟❗️📚

Don’t miss ‘W10 Cellular therapy in other disease’ on April 17 (10:30 – 11:45 bst) at #EBMT24. Overview, new insights & recommendations (library.ebmt.org/category4/docu…) on the use of #CART #TCR in #autoimmunediseases and #solidtumors 
@TheEBMT @TheEBMT_Trainee 
🌟❗️📚
account_circle